NK
NKGen Biotech, Inc. Common Stock
NKGN · OTC
$0.01 +0.00% (+$0.00)
1M +471.43%
Market Cap $1.57M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
91 /100
Cheap P/S 2.40x
EV/EBITDA 1.85x
PEG N/A
Growth
-
N/A Book val. growth N/A
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak FCF margin 3,021.32%
Op. margin 3,682.67%
Gross margin 50.00%
Quality
58 /100
Average ROA 148.68%
Asset turnover 0.04x
ROIC 2,118.41%
Debt
45 /100
Moderate Int. coverage 3.08x
Net debt/EBITDA 1.77x
Current ratio 0.05x
Stability
37 /100
Moderate EPS volatility 211.35%
Profitable years 0
Beta 0.72x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o NKGN
Online
O podjetju
NKGen Biotech, Inc. Common Stock (NKGEN) is a biotechnology company specializing in the development and research of therapeutic products utilizing natural killer (NK) cells. Their main focus is on harnessing the body's immune system to fight against cancer and other diseases.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Paul Y. Song
Employees
26
Headquarters
Santa Ana